A top-50 sponsor found data manipulation at a Phase II site; CluePoints' platform flagged it retrospectively and could catch it earlier.
Suspicious creatinine clearance values at one site were confirmed as manipulation by audit, while the sponsor's existing central monitoring platform could not flag it in time. CluePoints' Central Monitoring Platform with Data Quality Assessment detected the issue retrospectively. The page gives no quantified metrics.
CluePoints is a risk-based quality management and central statistical monitoring platform used by sponsors and CROs to detect data quality, fraud and safety issues in trials
This sits in the Ship stage of the AI use-case lifecycle: Named examples from the vendors pharma teams use to get an AI system live inside a real, regulated production workflow — validation, CRM, safety and clinical systems of record.
Published by CluePoints on its own site — read the original case study on cluepoints.com ↗
Related use cases
- 01A CRO cut monitoring costs by over 50% on a global Phase IV oncology study using CluePoints' risk-based approach.
- 02CluePoints' data quality assessment exposed a systemic issue behind one positive outlier in a Phase I neurology study.
- 03CluePoints' central monitoring caught missing gluten tests and misclassified adverse events in a trial of fewer than 50 subjects.
- 04A dermatology company monitored 24+ sites and 680 participants in a Phase 3 study with CluePoints' ML-based RBQM.
- 05Transforming Content Operations for 2x Faster Time to Market
- 06Astellas: Breaking Access Barriers with Veeva Compliant Chat